H19 and ovarian cancer: Also, phase I/II clinical trials are underway in patients with bladder, pancreatic and ovarian cancers for lncRNA H19 targeted therapy based on in vitro experiments demonstrating tumor cell growth arrest without affecting normal cells with H19 promoter cloned into BC-819 plasmid [16–18].